COMPANY

Outpace Bio

HQ: Seattle, WA source · outpacebio.com ↗ · West Coast

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Endometrial Cancer Ovarian Cancer Ovarian Cancer Recurrent Platinum Resistant Ovarian Cancer Endometrial Cancer Recurrent Advanced Endometrial Cancer OPB-201 OPB-101

2Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $144M · announced Aug 1, 2024 Company release ↗
Source quote
- Aug 1, 2024 · Company release ↗
  “With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies”

Raises announced in these releases: $144M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jun 30, 2026 Trial start 1: A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. source ↗
Jun 16, 2025 Trial start Phase 1: A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer source ↗
Aug 1, 2024 Raise Series B · $144M source ↗

Upcoming milestones

May 15, 2028 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer · NCT07030907
2030-06 (ESTIMATED) · 1 · A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. · NCT07664735

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07664735	A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.	1	Not yet recruiting	Jun 30, 2026	2030-06 (estimated)
NCT07030907	A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer	Phase 1	Recruiting	Jun 16, 2025	May 15, 2028 (estimated)